Acrylamide (AC) is an organic amide classified as a hepatotoxic compound. Its presence in cigarette smoke and some processed foods represents a hazard to humans. As a natural food with a high nutritional content, royal jelly (RJ) is used in the protection and therapy of several diseases that affect humans. This research examined the possibility of using RJ to improve hepatotoxicity caused by AC. The study included four groups of rats (each 6 rats): the first group was given oral saline (control group); the second group was given an oral dose of AC (38.27 mg/kg dissolved in saline); and the third and fourth groups received oral RJ an hour before the AC administration at 150 mg/kg (150 RJ + AC group) and 300 mg/kg (300 RJ + AC group), respectively. The trial period extended to 10 consecutive days. On the 11th day, blood and liver samples were obtained from rats in each group for biochemical, histological, and immunohistochemical examinations. The sera of AC-treated rats showed an elevated hepatic function panel, mild hyperglycemia, and dyslipidemia, while their hepatic tissues showed histological changes, oxidative stress, and inflammation. Administration of RJ at 150 and 300 mg/kg doses to AC-treated rats improved the hepatic function panel, blood glucose, lipid panel, histological changes, oxidative stress, and inflammation in the hepatic tissue. In conclusion, RJ was able to ameliorate hepatic dysfunction, mild hyperglycemia, and dyslipidemia, as well as improve histological changes, inflammation, and oxidation in the hepatic tissue induced by AC in rats.